The endocannabinoids (eCBs) anandamide and 2-arachidonoylglycerol are important retrograde messengers that inhibit neurotransmitter release via presynaptic CB 1 receptors. In addition, cannabinoids are known to modulate the cell death/survival decision of different neural cell types, leading to different outcomes that depend on the nature of the target cell and its proliferative/differentiation status. Thus, cannabinoids protect primary neurons, astrocytes and oligodendrocytes from apoptosis, whereas transformed glial cells are prone to apoptosis by cannabinoid challenge. Moreover, a potential role of the eCB system in neurogenesis and neural differentiation has been proposed. Recent research shows that eCBs stimulate neural progenitor proliferation and inhibit hippocampal neurogenesis in normal adult brain. Cannabinoids inhibit cortical neuron differentiation and promote glial differentiation. On the other hand, experiments with differentiated neurons have shown that cannabinoids also regulate neuritogenesis, axonal growth and synaptogenesis. These new observations support that eCBs constitute a new family of lipid signaling cues responsible for the regulation of neural progenitor proliferation and differentiation, acting as instructive proliferative signals through the CB 1 receptor.
THE ENDOCANNABINOID SYSTEM
Anandamide (AEA, N-arachidonoylethanolamine) and 2-arachidonoylglycerol (2AG) were the first endocannabinoids (eCBs) discovered [1] [2] [3] in the search for the endogenous ligands of cannabinoid receptors, the molecular targets of the psychoactive components of Cannabis sativa [4, 5] . Other putative eCB ligands such as noladin ether, virodhamine and various N-acylethanolamines have been described, but their precise biological relevance is still unknown [5] . eCB synthesis, by cleavage of plasma membrane precursors, is specifically regulated by neuronal activity. This process is usually Ca 2+ -dependent, although Ca 2+ -independent eCB generation has also been reported [5, 6] . Once generated, eCBs act retrogradely through presynaptic CB 1 receptors, blunting membrane depolarization and thereby inhibiting neurotransmitter release [6] . Cannabinoid signaling is terminated by their uptake and subsequent degradation. Thus, the concept of the "eCB system" includes these endogenous lipid ligands and their receptors, together with their specific mechanisms of synthesis and clearance.
The CB 1 receptor is a seven-transmembrane receptor [7] coupled to Gi-mediated inhibition of adenylyl cyclase and modulation of ion channels, including inhibition of voltagedependent Ca 2+ channels (N, P/Q type) and activation of inwardly-rectifying K + channels [4] . In addition, cannabinoids activate different signaling pathways involved in the regulation of cell fate such as the mitogen-activated protein kinase family (extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase and p38), Akt and the sphingolipid pathway [8] .
*Address correspondence to this author at the Dept Biochemistry and Molecular Biology I, School of Biology, Complutense University, 28040 Madrid, Spain; Tel: (34) 913944668; Fax: (34) 913944672; E-mail: igr@quim.ucm.es During brain development a tight control of cell proliferation and death occurs in order to guarantee the generation of the appropriate number of neural cells. Besides the important neuromodulatory role of eCBs [5, 6] , it is now becoming evident that these lipid mediators are also involved in the regulation of neural cell commitment and survival [8] [9] [10] [11] . Here we review: i) the protective role of eCBs upon brain injury; ii) their effects on neural progenitor cell proliferation and differentiation; iii) their actions on neuritogenesis and synaptogenesis. Finally, the postulated signaling mechanisms responsible for eCB regulation of neural cell fate and the potential pathophysiological implications are discussed.
ENDOCANNABINOID PROTECTION OF NEURONS AND GLIA
The eCB system appears to play a role in the neuroprotective response to a variety of insults such as traumatic brain injury, ischemia, excitotoxicity and oxidative stress [10] . Thus, neurodegeneration induced by global or focal cerebral ischemia is prevented in vivo by injection of the synthetic cannabinoid WIN-55,212-2 in a CB 1 -dependent manner [12] . Moreover, ∆ 9 -tetrahydrocannabinol (the most potent and abundant plant-derived cannabinoid) and AEA reduce the brain infarct volume in a ouabain-induced model of excitotoxicity, as determined by magnetic resonance imaging [13] . Similarly, harmful consequences of traumatic brain injury such as edema and neuronal cell death are decreased as a consequence of increased 2AG levels [14] . The involvement of the CB 1 receptor in eCB-mediated neuroprotection is further supported by elegant experiments performed with knock-out animals. Thus, CB 1 -defective animals are more susceptible to stroke-induced neuronal death [15] and kainic acid-induced excitotoxicity [16] . The use of CB 1 knock-out animals in which receptor expression is abolished exclusively in principal forebrain neurons, but not in GABAergic interneurons, indicates a direct action of the CB 1 receptor within the same neuronal cells susceptible for primary excitotoxicity damage. In addition, several brain insults induce a selective increase in certain eCB species, further suggesting a protective role for these molecules. Traumatic brain injury enhances 2AG levels [14] , whereas glutamatergic excitotoxicity increases AEA but neither 2AG nor N-palmitoylethanolamine levels [16, 17] . In addition, focal cerebral ischemia selectively rises N-palmitoylethanolamine levels [18] . The biological meaning for this apparent selectivity of the eCB molecular species generated upon different brain insults is still unknown. In this respect, it could be argued that eCB production may be the consequence of the cytotoxic environment occuring upon brain injury, in which high intracellular Ca 2+ concentration [19] would stimulate eCB production by both neurons and glial cells [5] . It is also worth noting that other studies have shown the existence of eCB neurotoxic actions [20] [21] [22] , an effect that probably reflects the ability of AEA to modulate vanilloid receptor TRPV1 [11] (Fig. 1) . Finally, the potential influence of the eCB system in the balance between cell death and proliferation during nervous system development remains to be elucidated.
Cannabinoids also protect glial cells from apoptosis both in vivo and in vitro . WIN-55,512-2 protects astrocytes from focal ceramide injection [23] , and this "astroprotective" effect can be also reproduced in cell culture models [23] [24] [25] . Moreover, cannabinoids protect oligodendrocytes from growth factor deprivation-induced cell death [26] , and additionally in vivo they prevent demyelination in the Theiler virus-induced model of multiple sclerosis [27] . Therefore, cannabinoid-induced prevention of neural cell death is not restricted to neurons. This could be important as protection of more than one type of cells within the brain may result in a synergistic action by increasing the efficiency of the injured-brain response. For instance, glial cell protection could contribute, at least in part, to the observed neuroprotection as glial cells are known to provide neurons with essential survival factors and nutrients.
Mechanism of Action
The precise molecular mechanism for cannabinoidmediated neuroprotection its not fully understood. Various cannabinoids with phenolic structure exert a CB 1 -independent neuroprotective effect owing to their antioxidant properties [28, 29] . However, this antioxidant mechanism cannot account for the observed CB 1 -mediated neuroprotective action of cannabinoid ligands. In this respect, probably the best described mechanism is the cannabinoid inhibitory action on presynaptic glutamate release that would protect cells from excitotoxicity [6, 30, 31] . In addition, on-demand eCB production has been shown to correlate with increased brainderived neurotrophic factor mRNA levels in the hippocampi of kainic acid-treated mice [16] . Furthermore, inhibition of nitric oxide production and proinflammatory cytokine release by activated microglial cells may also contribute to the neuroprotective action of eCBs [4] . By preventing an excessive amount of proinflammatory cytokines, eCBs could keep their levels in a range in which their action is beneficial rather than detrimental [32] .
It has been demonstrated that cannabinoids, via CB 1 receptors, activate at least two important survival signaling pathways involved in their protective effect: the phosphatidylinositol 3-kinase/Akt pathway [23, 24, 26, 33, 34] and the ERK pathway [9, 23, 24] (Fig. 1) . Both pathways appear to act in concert upon CB 1 activation and Gi protein dissociation [24, 35] . CB 1 coupling to adenylyl cyclase inhibition may suppress cAMP-mediated Raf-1 inhibition [36] [37] [38] . Additionally, CB 1 engagement may transactivate growth factor tyrosine kinase receptors [39] [40] . Cannabinoid pro-survival effect in glial cells may be therefore explained by a double mechanism that involves phosphatidylinositol 3-kinase/Akt and ERK signaling.
ENDOCANNABINOID STIMULATION OF NEURAL PROGENITOR CELL PROLIFERATION
Endocannabinoids have recently been shown to modulate neuronal differentiation in a variety of cell models. AEA stimulation inhibits both rat cortical neuron differentiation and nerve growth factor-initiated PC12 neuronal-like cell differentiation. The CB 1 receptor, which is expressed in neural progenitors, is responsible for cannabinoid-induced inhibition of neurogenesis as shown by blockade with the CB 1 antagonist SR141716. eCBs decrease the expression of the neuronal markers β-tubulin III and Neu N, specific for early and mature differentiated neurons, respectively, and results in lower number of neurite-bearing cells. No changes in cell viability and neurite remodelling were observed after AEA challenge. Therefore, eCB action seems to rely on a direct modulation of the endogenous differentiation program of neural progenitors [41] . In fact, cannabinoid inhibition of neurogenesis occurs in parallel with increased hippocampal neural progenitor proliferation [42] and gliogenesis [Authors' unpublished observations]. Importantly, eCB modulation of neural progenitor differentiation is relevant in vivo. Thus, when adult rats are treated with methanandamide, a nonhydrolizable AEA analogue, together with 5-bromo-2'-deoxyuridine (BrdU), which labels newly-generated cells, a significant decrease in hippocampal neurogenesis (NeuN + / BrdU + ) was observed [41] . Moreover, SR141716 administration increased neuronal differentiation of endogenous neural progenitors, pointing to the existence of an endogenous cannabinoid tone actively modulating neural progenitor differentiation through the CB 1 receptor [41] [42] [43] . This hypothesis has been corroborated in knock-out mice. Deletion of the deactivating eCB enzyme, fatty acid amide hydrolase (FAAH), results in increased hippocampal proliferation, whereas the opposite occurs in CB 1 -deficient neural progenitors [42, 43] . eCBs might target in brain various receptors different from CB 1 . For instance, "ionotropic-like" cannabinoid receptors have been proposed, including the vanilloid receptor TRPV1 [4, 6, 11] , T-type α1H Ca 2+ channels [44] , background K + channel TASK [45] and 5HT3A receptors [46] . In vitro experiments with neuroblastoma cells have shown that AEA, but not other cannabinoids such as 2AG or WIN-55,212-2, inhibits neuronal differentiation in a CB 1 -independent manner [47] . AEA action in this model occurs intracellularly through a direct inhibitory effect on T-type α1H calcium channels, which are essential for neuronal differentiation and neuritogenesis [44] . In this context, we have re-cently investigated the role of the CB 1 receptor in a model of adult rat neurogenesis employing WIN-55,212-2, which does not bind to "ionotropic-like" cannabinoid receptors [4] . As shown in Fig. (2) , WIN-55,212-2 administration significantly reduced the number of newly-generated neuronal cells in the subgranular zone of the dentate gyrus in a CB 1 -dependent manner, as evidenced by SR141716 prevention. This is in line with our previous results [41] and clearly implicates the CB 1 receptor in the regulation of neural progenitor cell fate in vivo. The existence of a CB 1 -independent neurogenic modulatory mechanism is however possible [43] and might be specific for AEA as a ligand, whereas CB 1 -mediated modulation of neural progenitor differentiation and commitment seems to be a more general mechanism of cannabinoid regulation of neurogenesis.
Mechanism of action
The molecular mechanism responsible for eCB inhibition of neuronal differentiation through the CB 1 receptor was studied employing a PC-12 cell paradigm of neuronal-like differentiation. Although ∆ 9 -tetrahydrocannabinol injection activates ERK in the hippocampus [37] , cannabinoid stimulation of cultured neuronal cells, in contrast to glial cells, does not activate the ERK signaling pathway [41, 48] . In fact, cannabinoids decrease nerve growth factor-induced ERK activation by a mechanism that involves the inhibition of the upstream signaling proteins Rap1 and B-Raf [41] (Fig. 3) . Most likely, one of the reasons for the opposite effects of cannabinoids in ERK regulation in glial versus neuronal cells is that neurons express significant amounts of B-Raf, which Fig. (1) . CB 1 -mediated PI3K/Akt and ERK activation is involved in cannabinoid glioprotective action. CB 1 activation results in heterotrimeric G i protein dissociation and βγ-subunit release, thereby activating the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway. In addition, Raf-1 is activated in a PI3K-dependent manner but independently of tyrosine kinase growth factor receptors. When intracellular cAMP levels are elevated, CB 1 -mediated inhibition of adenylyl cyclase (AC) may also contribute to supress cAMP-mediated Raf-1 inhibition. Pro-survival cannabinoid action is thus achieved through Akt and ERK downstream signaling targets. AEA neurotoxic actions via TRPV1 have also been reported. is barely detectable in glial cells [49] . The Rap1/B-Raf signaling branch of the ERK pathway, although interconnected with the classical Ras/Raf-1 branch, has been shown during Fig. (2) . Cannabinoid inhibition of adult rat hippocampal neurogenesis is mediated by the CB 1 receptor. Percentage of BrdUpositive cells that colocalize or not with the mature neuronal marker Neu N in the dentate gyrus of rats treated with vehicle (n=5), WIN-55,212-2 alone (n=5) or together with SR141716 (n=4) and SR141716 alone (n=4). Adult Wistar rats were injected i.p. with 1 mg/kg/day WIN-55,212-2 alone or in combination with 1 mg/kg/day SR141716 dissolved in PBS/Tween 80/ethanol (18:1:1 v/v/v; 1 ml/kg body weight), or equal amounts of vehicle for 4 consecutive days. At day 2 of cannabinoid treatment, 100 mg/kg 5-bromo-2'-deoxyuridine (BrdU) was administered together with the cannabinoid, and a second injection of BrdU alone was performed 2 h later. Thereafter, animals received the cannabinoid treatment on alternate days until perfusion on day 16 in order to allow newly generated cells to acquire appropriate neuronal phenotype and functionality. Significantly different from controls *P< 0.05, **P < 0.01. the last years to play a specific role in sustained ERK activation [50] . Importantly, depending on the intensity, duration and mechanism of ERK activation, different cellular responses such as proliferation or differentiation may ensue. Sustained ERK activation is known to be required for neuronal differentiation [50] , and during cortical development sustained MEK/ERK signaling is necessary for neurogenesis and concomitant inhibition of gliogenesis [51] . In fact, expression of B-Raf is required for the neuronal response to several neurotrophins including nerve growth factor [50] , and therefore its pattern of expression should be regulated during central nervous system development. These observations correlate with the ability of cannabinoids to inhibit Rap-1/B-Raf-mediated sustained ERK activation, which results in inhibition of neuronal differentiation [41] . Moreover, cannabinoid regulation of the ERK pathway through the CB 1 receptor is known to be involved in the regulation of cell death/survival balance in a variety of neural and non-neural cell models [9] .
ENDOCANNABINOID INHIBITION OF NEURITO-GENESIS AND SYNAPTOGENESIS
Recent evidence has accumulated indicating that eCBs inhibit neuritogenesis and synaptogenesis. AEA and the synthetic cannabinoid agonist HU-210 induce neuroblastoma cell rounding and neurite retraction via CB 1 receptor [52, 53] . In contrast, HU-210 has been reported to promote neurite outgrowth in Neuro-2A cells by Gα o/i mediated RapGAPII degradation and subsequent Rap1 activation [54] . In agreement with a potential role of eCBs in the regulation neuritogenesis, WIN-55,212-2 and AEA stimulation of rat hippocampal neurons decreases forskolin-induced synapse formation as determined by a FMI-413-based assay [55] . Moreover, long-term (21-day long) subcutaneous treatment of adult rats with WIN-55,212-2 induces hippocampal morphological changes, with decreased MAP-2 staining in CA1 and increased MAP-2-positive dendrites in CA3 [56] . On the other hand, 2AG generation has been postulated to mediate fibroblast growth factor-mediated stimulation of axonal growth in cerebelar neurons [57] , although confirmation of this attractive hypothesis would require direct evidence of increased eCB levels upon growth factor stimulation. Fig. (3) . CB 1 -mediated blockade of the Rap1/B-Raf/ERK pathway is involved in cannabinoid inhibition of neural differentiation. eCB engagement of the CB 1 receptor leads to the inhibition of nerve growth factor-mediated TrkA activation and adenylyl cyclase (AC) inhibition. Thus, Rap1 and B-Raf activation is blunted and sustained downstream ERK signaling decreases. As prolonged ERK activity is required for neuronal differentiation, ECBs inhibit neuronal marker expression and neurogenesis. Rap1 activation via GTPase-activating protein (RapGAP) turnover has also been reported.
It is worth noting that cannabinoid regulation of neuritogenesis and synaptogenesis shows a clear parallelism with the actions of other well known neural bioactive lipids such as lysophosphatidic acid (LPA) [58, 59] and sphingosine-1-phosphate (SPP) [60, 61] . Both LPA and SPP are able to induce neurite retraction through their specific seven-trans- [62, 63] . Receptor coupling to Rho-initiated signaling events mediates the cytoskeletal changes involved in neurite remodelling by LPA and SPP [59, 60] , and similarly AEA-induced neurite retraction relies on Rho kinase activation, as its specific inhibitor Y-27632 completely prevents eCB action [53] . Interestingly, these observations point to the existence of a functional coupling between the CB 1 receptor and heterotrimeric G 12/13 proteins that can drive Rho activation [64] . Cannabinoid receptors exhibit certain homology with Edg receptors, and thereby are considered as part of the same G protein-coupled receptor family [62] . In addition, as discussed above for eCBs, both LPA [65] and SPP [66] have been recently shown to influence cortical cell growth and neural progenitor proliferation. Altogether, these observations support that eCBs, together with other bioactive lipids such as LPA and SPP, participate via specific membrane receptors in the regulation of brain development and neurite dynamics.
PATHOPHYSIOLOGICAL IMPLICATIONS
eCB levels and CB 1 receptor expression are characterized by a developmentally regulated pattern [67, 68] , pointing to a role for the eCB system in the regulation of nervous system formation. This notion is further supported by the aforementioned cannabinoid actions on neuritogenesis and synaptogenesis and their ability to regulate neural progenitor commitment and differentiation. In the adult brain, the CB 1 receptor is present at high levels in the hippocampus, which at least partially explains cannabinoid disruption of cognitive processes such as learning and short-term memory [5, 6] . Adult neurogenesis is proposed to be involved in cognitive functions [69] as newly-born neurons are functionally equivalent to neurons generated during development and become rapidly incorporated into functional hippocampal circuits [70] . In fact, hippocampal-dependent forms of memory are influenced by adult neurogenesis [69] , and memory performance of aged rats is related to hippocampal neurogenesis levels [71] . Thus, besides cannabinoid-mediated neuromodulation and inhibition of hippocampal cell firing [5, 6] , cannabinoid regulation of neurogenesis in adult hippocampus might interfere with cognitive processes [41, 55, 56] . In this respect, eCB inhibition of Rap1/B-Raf signaling in neurons [41] might be related with the recent demonstration that Rap1-initiated signaling is essential for hippocampaldependent memory and synaptic plasticity [72] .
As discussed above, the eCB system may be part of the injured-brain response and act as a potent neuroprotective signal [10] . Brain insults selectively increase eCB levels, which can protect mature neurons and glia from death. In addition, eCBs stimulate hippocampal neural progenitor proliferation in a CB 1 -dependent manner [42] . Considering that the injured brain exhibits features that facilitate functional adult neurogenesis [73] , eCB stimulation of neural progenitor proliferation may represent a mechanism for the injured brain to expand the endogenous population of neural progenitors in order to minimize the intensity of the damage.
CONCLUDING REMARKS
The recent advances reviewed here highlight the potential role of the eCB system in the regulation of crucial neural progenitor cell biology events such as proliferation and differentiation. eCBs should be considered as a new family of extracellular bioactive lipids that participate in brain development and repair, either directly or by modulating other endogenous signaling cues [74] . Moreover, owing to the important pathophysiological implications of adult neurogenesis, pharmacological targeting of the eCB system constitutes an attractive approach for the development of new strategies directed to promote brain repair. 2003) and Fundación Científica de la Asociación Española Contra el Cáncer. 
